Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Director Richard F. Pops sold 5,500 shares of Neurocrine Biosciences stock in a transaction dated Monday, October 29th. The stock was sold at an average price of $107.13, for a total value of $589,215.00. Following the sale, the director now owns 37,759 shares in the company, valued at approximately $4,045,121.67. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
NASDAQ NBIX opened at $107.15 on Thursday. The company has a debt-to-equity ratio of 1.00, a quick ratio of 9.19 and a current ratio of 9.19. Neurocrine Biosciences, Inc. has a 52-week low of $60.38 and a 52-week high of $126.98. The stock has a market cap of $9.70 billion, a P/E ratio of -66.14, a P/E/G ratio of 33.70 and a beta of 0.55.
Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings results on Tuesday, July 31st. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.18) by $0.11. Neurocrine Biosciences had a negative return on equity of 14.22% and a negative net margin of 16.07%. The firm had revenue of $96.90 million for the quarter, compared to analyst estimates of $84.11 million. During the same quarter last year, the company posted ($0.68) earnings per share. The business’s revenue was up 1428.4% on a year-over-year basis. Analysts predict that Neurocrine Biosciences, Inc. will post 0.15 earnings per share for the current fiscal year.
A number of analysts have recently commented on the company. Piper Jaffray Companies set a $115.00 target price on Neurocrine Biosciences and gave the stock a “buy” rating in a research report on Friday, October 5th. Stifel Nicolaus lifted their target price on Neurocrine Biosciences from $137.00 to $142.00 and gave the stock a “buy” rating in a research report on Thursday, September 20th. Cantor Fitzgerald set a $150.00 target price on Neurocrine Biosciences and gave the stock a “buy” rating in a research report on Thursday, September 20th. BidaskClub cut Neurocrine Biosciences from a “buy” rating to a “hold” rating in a research report on Saturday, September 15th. Finally, Oppenheimer set a $140.00 price target on Neurocrine Biosciences and gave the stock a “buy” rating in a report on Wednesday, September 12th. One research analyst has rated the stock with a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $122.22.
Neurocrine Biosciences Company Profile
Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's lead products include INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; elagolix, a gonadotropin-releasing hormone (GnRH) antagonist that is in Phase III clinical trial for use in women's health; and opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trial that is used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease.
Recommended Story: How Do You Calculate Return on Equity (ROE)?
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.